Stage 4 lung cancer means the cancer has spread beyond the lungs to distant parts of the body. It is the most advanced stage, and roughly half of all lung cancers are already at this point when first diagnosed. The five-year relative survival rate for metastatic lung cancer is 10.5%, based on cases tracked by the National Cancer Institute’s SEER database from 2016 to 2022. That number is an average across all patients, and individual outcomes vary widely depending on where the cancer has spread, the tumor’s genetic profile, and which treatments are available.
What “Stage 4” Actually Means
Lung cancer staging describes how far the disease has traveled from where it started. In stages 1 through 3, the cancer is confined to the chest, though it may involve nearby lymph nodes or structures. Stage 4 is defined by spread to a distant organ or to fluid around the heart or lungs that contains cancer cells.
Stage 4 is divided into two substages. Stage 4A means the cancer has spread to a limited number of sites, such as a single spot in the opposite lung, a single distant organ, or malignant fluid around the lungs or heart. Stage 4B means there are multiple tumors in one or more distant organs. The distinction matters because stage 4A may sometimes be treated more aggressively than 4B.
Where Stage 4 Lung Cancer Spreads
The most frequent sites of metastasis are the brain and nervous system, bones, liver, the other lung, and the adrenal glands (small hormone-producing glands on top of the kidneys). The pattern depends partly on the type of lung cancer. In adenocarcinoma, the most common form of non-small cell lung cancer, bone metastases occur in about 39% of patients with distant spread, and lung-to-lung spread in roughly 22%. Small cell lung cancer tends to favor the brain (47%) and liver (35%).
Each metastatic site creates its own set of problems, which is why stage 4 lung cancer can look very different from one person to the next.
Symptoms at This Stage
Symptoms come from two sources: the original tumor in the lungs and the new growths wherever the cancer has landed. In the chest, people commonly experience a persistent cough, chest pain that worsens with deep breathing or laughing, shortness of breath, hoarseness, and recurring respiratory infections like pneumonia that don’t fully clear.
Symptoms from metastatic sites depend on where the cancer has gone:
- Bones: Pain or unexpected fractures, often in the back or hips.
- Brain: Headaches, dizziness, seizures, memory problems, sleepiness, or numbness and weakness in an arm or leg.
- Liver: Yellowing of the skin and eyes (jaundice) or swelling in the abdomen.
- Lymph nodes: Visible or palpable swelling near the collarbone or in the neck.
- Adrenal glands: Often no symptoms at all unless the tumor grows large enough to cause abdominal or back pain.
Some people have few noticeable symptoms even with widespread disease, which is one reason lung cancer is so often caught late.
How It’s Diagnosed and Staged
Confirming stage 4 requires both tissue sampling and imaging. A biopsy provides the definitive cancer diagnosis. Doctors can collect tissue in several ways: threading a thin, lighted tube through the throat into the airways (bronchoscopy), inserting a needle through the chest wall into the lung, or making a small incision at the base of the neck to reach lymph nodes behind the breastbone.
Imaging determines how far the cancer has traveled. CT scans, PET scans, bone scans, and brain MRIs are commonly used together. A PET scan is especially useful because it highlights areas of abnormally high metabolic activity throughout the body, flagging potential metastases that a standard CT might miss. An MRI of the brain is routinely performed because brain metastases are so common in lung cancer and don’t always show symptoms early on.
Why Biomarker Testing Matters
Once a biopsy confirms non-small cell lung cancer, the tumor tissue is tested for specific genetic mutations and protein markers. This step is critical because certain mutations make the cancer vulnerable to drugs designed to target that exact abnormality. Without testing, those treatment options would be missed entirely.
The most well-known markers include mutations in EGFR, rearrangements in ALK, and levels of a protein called PD-L1 on the tumor surface. PD-L1 levels help predict whether immunotherapy is likely to work. Beyond those, there are now FDA-approved treatments linked to mutations in BRAF, ROS1, RET, MET, NTRK, and HER2 genes. Comprehensive genomic testing, often done through a single panel called next-generation sequencing, is strongly recommended for all patients with advanced non-small cell lung cancer to capture the full picture in one pass.
Treatment Options
Treatment for stage 4 lung cancer is not aimed at curing the disease in most cases. The goals are to slow growth, shrink tumors, relieve symptoms, and extend life. What you receive depends heavily on your biomarker results, overall health, and the type and extent of spread.
Targeted Therapy
If your tumor carries a treatable mutation, targeted therapy is typically the first choice. These are oral or infusion drugs that block the specific molecular pathway driving your cancer’s growth. For example, patients with EGFR mutations may receive a daily pill that specifically inhibits that protein. Targeted therapies often produce strong responses with fewer of the harsh side effects associated with traditional chemotherapy, and some can control the disease for a year or longer before resistance develops.
Immunotherapy
For tumors without a targetable mutation, immunotherapy has become a cornerstone of treatment. These drugs work by helping your immune system recognize and attack cancer cells it was previously ignoring. Immunotherapy can be given alone or combined with chemotherapy, depending on PD-L1 levels and other factors. Some patients respond remarkably well, with a small percentage achieving long-term disease control lasting years.
Chemotherapy
Chemotherapy remains part of the treatment landscape, often combined with immunotherapy as a first-line approach. Platinum-based combinations are standard. Chemotherapy is also used when targeted therapy isn’t an option or when the cancer progresses on other treatments. It’s typically given in cycles, with rest periods in between to allow the body to recover.
Radiation
Radiation in stage 4 is most often used to manage specific problems rather than treat the whole disease. It can relieve pain from bone metastases, shrink brain tumors, or open blocked airways. In select cases where the cancer has spread to only one or two spots, focused radiation to those sites (sometimes called stereotactic radiation) may be considered alongside systemic treatment.
Palliative Care Is Not the Same as Hospice
Palliative care focuses on comfort, symptom management, and quality of life, and it can start the day you’re diagnosed. It runs alongside active cancer treatment. A palliative care team helps manage pain, breathing difficulties, nausea, fatigue, and the emotional weight of living with advanced cancer. Research consistently shows that people with stage 4 lung cancer who receive early palliative care report better quality of life and, in some studies, live longer than those who don’t.
Hospice is a specific form of palliative care reserved for patients whose illness is no longer responding to treatment and whose life expectancy is estimated at six months or less. In hospice, curative or disease-directed treatments stop, but comfort-focused medical care continues. The shift to hospice doesn’t mean giving up all medication. It means the focus moves entirely to comfort, dignity, and support for both the patient and their family.
What Affects Survival
The 10.5% five-year survival rate for metastatic lung cancer is a population-level statistic that blends together every type, mutation, and treatment response. Individual prognosis can look quite different. Patients with certain targetable mutations, particularly ALK rearrangements or some EGFR mutations, often survive significantly longer than that average suggests. People who respond well to immunotherapy can also outlive statistical expectations by a wide margin.
Factors that influence outcomes include the number and location of metastases, overall physical fitness at diagnosis, the tumor’s molecular profile, and how well the cancer responds to initial treatment. Stage 4A, with limited spread, generally carries a better outlook than 4B. Survival rates have been improving steadily over the past decade as targeted therapies and immunotherapies have expanded the treatment toolkit, and approvals for new drugs continue at a faster pace than in previous years.